SINGAPORE, Sept. 30, 2026 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the company's next phase of growth.
kAm|:4926= 3C:?8D @G6C b_ J62CD @7 8=@32= r#~ :?5FDECJ 6IA6C:6?46] w6 ;@:?D t>6C2=5 r=:?:42= 27E6C D:I J62CD H:E9 }@G@E649 H96C6 96 H2D r9:67 ~A6C2E:?8 ~77:46Cj AC:@C E@ E92E 96 H2D rt~ 2E !!r vC@FA 7@C E9C66 J62CD 2?5 DA6?E aa J62CD H:E9 x"'xp :? D6G6C2= C68:@?2= 2?5 8=@32= =6256CD9:A A@D:E:@?D] w6 92D 96=A65 E96D6 @C82?:K2E:@?D E9C@F89 4@>A=6I EC2?D7@C>2E:@?D[ 5C:G:?8 D:8?:7:42?E C6G6?F6 8C@HE9 2?5 >2C<6E =6256CD9:A[ H:E9 566A @A6C2E:@?2= 6IA6C:6?46 24C@DD pD:2\!24:7:4[ :?4=F5:?8 r9:?2[ $:?82A@C6 2?5 pFDEC2=:2]k^Am
kAmw:D 2AA@:?E>6?E 7@==@HD 2 EC2?D7@C>2E:G6 J62C 7@C t>6C2=5 r=:?:42=[ :?4=F5:?8 E96 24BF:D:E:@? @7 w@?8J: r=:?:42= s6G6=@A>6?E $6CG:46D] %96 4@>3:?2E:@? 4C62E65 2 F?:BF6=J A@D:E:@?65 4=:?:42= 56G6=@A>6?E A=2E7@C> @7 >@C6 E92? `[___ AC@76DD:@?2=D 24C@DD c_Z 4@F?EC:6D 2?5 f_Z =@42E:@?D[ DFAA@CE:?8 DA@?D@CD 7C@> 7:CDE\:?\9F>2? EC:2=D E9C@F89 A@DE\>2C<6E:?8 24C@DD r9:?2[ pD:2\!24:7:4[ tFC@A6 2?5 E96 p>6C:42D]k^Am
kAmQ|:4926= :D E96 C:89E =6256C 7@C t>6C2=5 r=:?:42=VD ?6IE 492AE6C @7 8C@HE9[Q D2:5 $62? r2C?6J[ r92:C>2? @7 E96 q@2C5] Qw6 4@>3:?6D AC@G6? @A6C2E:@?2= DEC6?8E9[ 2 8=@32= A6CDA64E:G6[ 2?5 566A pD:2\!24:7:4 6IA6C:6?46 H:E9 2 EC24< C64@C5 @7 E2<:?8 3FD:?6DD6D E@ E96 ?6IE =6G6=] ~? 3692=7 @7 E96 q@2C5[ x E92?< v=6?? z6C<9@7[ H9@D6 =6256CD9:A 2D x?E6C:> rt~ 56=:G6C65 8C@HE9 2?5 4@?E:?F65 6I46==6?46 7@C @FC 4FDE@>6CD] v=6?? C6>2:?D @? E96 q@2C5 2?5 4@?E:?F6D E@ 25G:D6 E96 4@>A2?J]Qk^Am
kAmQ%96 @FE=@@< 7@C @FC :?5FDECJ 92D ?6G6C 366? >@C6 6I4:E:?8i 8=@32= 4=:?:42= 56G6=@A>6?E :D @? 2 DFDE2:?65 8C@HE9 A2E9 2D :??@G2E:@? A:A6=:?6D 6IA2?5 — 2?5 pD:2\!24:7:4 :D H96C6 E92E 8C@HE9 :D 72DE6DE] %96 7FEFC6 @7 4=:?:42= C6D62C49 H:== 36 D92A65 3J E96 2AA=:42E:@? @7 E649?@=@8:42= 25G2?46D 2E E96 :?E6CD64E:@? @7 8=@32= C6249 2?5 pD:2\!24:7:4 56AE9 — 2?5 ?@ 4@>A2?J D:ED >@C6 DBF2C6=J 2E E92E :?E6CD64E:@? E92? t>6C2=5 r=:?:42=[Q D2:5 |:4926= $E:3:=;[ r9:67 tI64FE:G6 ~77:46C] Q~FC 4@>>:E>6?E E@ @FC A6@A=6 2?5 4FDE@>6CD :D 4=62Ci 9:89\BF2=:EJ 56=:G6CJ[ DA665[ 2?5 EC2?DA2C6?4J :? 6G6CJE9:?8 H6 5@] x 2> 6I4:E65 E@ ;@:? 2 E62> H:E9 E9:D >F49 >@>6?EF>[ 2?5 x 2> 4@?7:56?E :? H92E H6 H:== 3F:=5 E@86E96C — 2 8=@32==J 4@>A6E:E:G6 r#~ 2?49@C65 :? pD:2\!24:7:4]Qk^Am
kAmkDEC@?8mp3@FE t>6C2=5 r=:?:42= %C:2=Dk^DEC@?8mk^Am
kAmt>6C2=5 r=:?:42= %C:2=D :D 2 8=@32=[ 7F==\D6CG:46 r#~ H:E9 @G6C ad J62CD @7 6IA6C:6?46[ A2CE?6C:?8 H:E9 `e_Z 3:@E649?@=@8J 4@>A2?:6D 2?5 `d @7 E96 H@C=5VD E@A a_ A92C>246FE:42= 7:C>D] w625BF2CE6C65 :? $:?82A@C6[ H:E9 `[___Z AC@76DD:@?2=D 24C@DD c_Z 4@F?EC:6D 2?5 2 4@==23@C2E:G6 ?6EH@C< DA2??:?8 f_Z =@42E:@?D[ t>6C2=5 56=:G6CD 6?5\E@\6?5 !92D6 x–x' 2?5 C62=\H@C=5 D@=FE:@?D[ H:E9 C64@8?:K65 D4:6?E:7:4 =6256CD9:A 24C@DD #6?2=[ ~?4@=@8J[ r2C5:@>6E23@=:4[ pFE@:>>F?6[ ~A9E92=>@=@8J[ 2?5 t2C=J !92D6 56G6=@A>6?E] x? r9:?2[ E96 4@>A2?J @A6C2E6D 2D t>6C2=5 r=:?:42= 弘翼临床] u@C >@C6 :?7@C>2E:@?[ G:D:E k2 9C67lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^=:?<^nEl_U2>Aj=l6?U2>Aj@lcfgddbf\`U2>Aj9lbhgbab__dfU2>AjFl9EEATbpTauTauHHH]6>6C2=54=:?:42=]4@>TauU2>Aj2lHHH]6>6C2=54=:?:42=]Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmHHH]6>6C2=54=:?:42=]k^2mk2 9C67lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^=:?<^nEl_U2>Aj=l6?U2>Aj@lcfgddbf\`U2>Aj9l`dab_dd_aeU2>AjFl9EEATbpTauTauHHH]6>6C2=54=:?:42=]4@>TauU2>Aj2l4@>Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQm4@>k^2m]k^Am
k5:G 4=2DDlQ!#}0x>365565pDD6E#676C6?46Q :5lQs:GpDD6E!=246w@=56CaQmkAmk:>8 DC4lQ9EEADi^^>>I]AC?6HDH:C6]4@>^>65:2^|$`eebcf`^v6@C86\r=:?:42=\t>6C2=5\r=:?:42=\%C:2=D\=@8@];A8n:5l~pahff_eeQ E:E=6lQt>6C2=5 r=:?:42= %C:2=DQ 2=ElQt>6C2=5 r=:?:42= %C:2=DQ ^mk^Amk^5:Gm
kA :5lQ!&#{Qmk:>8 E:E=6lQr:D:@?Q H:5E9lQ`aQ 96:89ElQ`aQ 2=ElQr:D:@?Q DC4lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^:>8^72G:4@?]A?8nD?lrvdhd__U2>AjD5la_ae\_h\b_Q ^m ':6H @C:8:?2= 4@?E6?E E@ 5@H?=@25 >F=E:>65:2ik2 :5lQ!#}&#{Q C6=lQ?@7@==@HQ 9C67lQ9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^6>6C2=5\4=:?:42=\EC:2=D\2AA@:?ED\>:4926=\DE:3:=;\2D\49:67\6I64FE:G6\@77:46C\E@\=625\?6IE\A92D6\@7\8=@32=\8C@HE9\b_aghcebd]9E>=Q E2C86ElQ03=2?<Qm9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^6>6C2=5\4=:?:42=\EC:2=D\2AA@:?ED\>:4926=\DE:3:=;\2D\49:67\6I64FE:G6\@77:46C\E@\=625\?6IE\A92D6\@7\8=@32=\8C@HE9\b_aghcebd]9E>=k^2mk^Am
kAm$~&#rt t>6C2=5 r=:?:42= %C:2=Dk^Am
kAmk:>8 2=ElQQ DC4lQ9EEADi^^CE]AC?6HDH:C6]4@>^CE]8:7n}6HDxE6>x5lrvdhd__U2>Aj%C2?D>:DD:@?0x5la_ae_hb_ab__!#0}t($0&$!#00000rvdhd__U2>Ajs2E6x5la_ae_hb_Q DEJ=6lQ3@C56Ci_AIj H:5E9i`AIj 96:89Ei`AIjQ ^mk^Am
